The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease

Kidney International Supplements

Volumn 7, Issue 2, 2017, Pages 130-137

  Pollock, Carol ^a   Zuk, Anna ^b   Anders, Hans Joachim ^c   Ganji, Mohammad Reza ^d   Johnson, David W ^e,f,g   Kasiske, Bertram ^h,i   Langham, Robyn G ^j   Pecoits Filho, Roberto ^k   Remuzzi, Giuseppe ^l,m,n   Rossert, Jerome ^o   Suzuki, Yusuke ^p   Tanaka, Tetsuhiro ^q   Walker, Robert ^r   Yang, Chih Wei ^s   Bonventre, Joseph V ^t  

^a UNIVERSITY OF SYDNEY   (Australia)

^b AKEBIA THERAPEUTICS   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f TRANSLATIONAL RESEARCH INSTITUTE   (Australia)

^g PRINCESS ALEXANDRA HOSPITAL   (Australia)

^h HENNEPIN COUNTY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^j MONASH UNIVERSITY   (Australia)

^k PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^l MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^m Unit of Nephrology   (Italy)

ⁿ UNIVERSITY OF MILAN   (Italy)

^o Thrasos Therapeutics Inc   (United States)

^p JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^q UNIVERSITY OF TOKYO   (Japan)

^r UNIVERSITY OF OTAGO   (New Zealand)

^s CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^t BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

drug re purposing; personalized medicine; targeted treatment

Indexed keywords

2 (2 CHLOROPHENYL) 4 [3 (DIMETHYLAMINO)PHENYL] 5 METHYL 1H PYRAZOLO[4,3 C]PYRIDINE 3,6(2H,5H) DIONE; ABATACEPT; ALEMTUZUMAB; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANIFROLUMAB; ATACICEPT; BARDOXOLONE METHYL; BLISIBIMOD; BORTEZOMIB; CORTICOTROPIN; CURCUMIN; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; FINERENONE; FOSTAMATINIB; INFLIXIMAB; LIRAGLUTIDE; LOSMAPIMOD; METFORMIN; OCTREOTIDE; PAMREVLUMAB; PHOSPHODIESTERASE V INHIBITOR; PIOGLITAZONE; RENIN INHIBITOR; RITUXIMAB; SACUBITRIL PLUS VALSARTAN; TOLVAPTAN; UNINDEXED DRUG;

ALPORT SYNDROME; ANCA ASSOCIATED VASCULITIS; BIOTECHNOLOGY; CHRONIC KIDNEY FAILURE; CLINICAL RESEARCH; COMORBIDITY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG TARGETING; END STAGE RENAL DISEASE; FOCAL GLOMERULOSCLEROSIS; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY POLYCYSTIC DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VALIDATION PROCESS;

EID: 85031747589     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1016/j.kisu.2017.07.008     Document Type: Review

References (28)

1. GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349 (1997), 1857–1863.
2. Mann, J.F.E., Schmieder, R.E., McQueen, M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372 (2008), 547–553.
3. Fried, L.F., Emanuele, N., Zhang, J.H., et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369 (2013), 1892–1903.
4. Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
5. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
6. Levin A, Tonelli M, Bonventre J, et al: Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy [e-pub ahead of print]. Lancet. http://dx.doi.org/10.1016/S0140-6736(17)30788-2. Accessed May 1, 2017.
7. Konstantinidis, I., Nadkarni, G.N., Yacoub, R., et al. Representation of patients with kidney disease in trials of cardiovascular interventions: an updated systematic review. JAMA Intern Med 176 (2016), 121–124.
8. Heerspink, H.J., Ninomiya, T., Zoungas, S., et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 373 (2009), 1009–1015.
9. Palmer, S.C., Navaneethan, S.D., Craig, J.C., et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev, 5, 2014, CD007784.
10. Ruggenenti, P., Porrini, E., Motterlini, N., et al. Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. J Am Soc Nephrol 23 (2012), 1717–1724.
11. Cice, G., Di Benedetto, A., D'Isa, S., et al. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol 56 (2010), 1701–1708.
12. Lv, J., Ehteshami, P., Sarnak, M.J., et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 185 (2013), 949–957.
13. Australian Institute of Health and Welfare. Cardiovascular disease, diabetes and chronic kidney disease—Australian facts mortality. Cardiovascular, diabetes and chronic kidney disease series no. 1. Cat. no. CDK 1. Canberra, Australia: Australian Institute of Health and Welfare, 2014.
14. Morrish, A.T., Hawley, C.M., Johnson, D.W., et al. Establishing a clinical trials network in nephrology: experience of the Australasian Kidney Trials Network. Kidney Int 85 (2014), 23–30.
15. Bello, A.K., Levin, A., Tonelli, M., et al. Assessment of global kidney health care status. JAMA 317 (2017), 1864–1881.
16. Parving, H.H., Brenner, B.M., McMurray, J.J.V., et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367 (2012), 2204–2213.
17. de Zeeuw, D., Akizawa, T., Audhya, P., et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. New Engl J Med 369 (2013), 2492–2503.
18. de Zeeuw, D., Bekker, P., Henkel, E., et al. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes Endocrinol 3 (2015), 687–696.
19. Bakris, G.L., Agarwal, R., Chan, J.C., et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 314 (2015), 884–894.
20. Scheele, W., Diamond, S., Gale, J., et al. Phosphodiesterase type 5 inhibition reduces albuminuria in subjects with overt diabetic nephropathy. J Am Soc Nephrol 27 (2016), 3459–3468.
21. Rauen, T., Eitner, F., Fitzner, C., et al. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med 373 (2015), 2225–2236.
22. Caroli, A., Perico, N., Perna, A., et al. Effect of long acting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet 382 (2013), 1485–1495.
23. Ruggenenti, P., Gentile, G., Perico, N., et al. Effect of sirolimus on disease progression in patients with autosomal dominant polycystic kidney disease and CKD stages 3b-4. Clin J Am Soc Nephrol 11 (2016), 785–794.
24. Torres, V.E., Chapman, A.B., Devuyst, O., et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367 (2012), 2407–2418.
25. Torres, V.E., Higashihara, E., Devuyst, O., et al. Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial. Clin J Am Soc Nephrol 11 (2016), 803–811.
26. Askanase, A., Byron, M., Keyes-Elstein, L., et al. Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol 66 (2014), 3096–3104.
27. Rovin, B.H., Furie, R., Latinis, K., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64 (2012), 1215–1226.
28. Ruggenenti, P., Ruggiero, B., Cravedi, P., et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol 25 (2014), 850–863.